Eli Lilly and Hims & Hers have agreed to make two of Lilly's obesity medicines available through the Hims & Hers telehealth platform. The agreement, announced on 6 November 2026, lets eligible patients who receive a prescription from a licensed provider on the platform buy Zepbound (tirzepatide) and Foundayo (orforglipron) at Lilly's self-pay prices, starting at $299 and $149 a month, without leaving the platform.
How the Arrangement Works
The patient journey stays inside one platform. A patient completes a consultation, receives a prescription if the provider determines it is appropriate, and has the medicine shipped directly to their home. Zepbound is a weekly injection. Foundayo is a once-daily oral tablet, and Lilly describes it as the daily oral option among its GLP-1 treatments. Both medicines are FDA-approved, and the prices are the same self-pay prices Lilly offers any patient.
The agreement also draws a clear line on compounded medicines. Hims & Hers has never offered compounded copies of Lilly's GLP-1 medicines, the companies said, and has committed not to do so in the future. The two companies also committed to protecting independent clinical decision-making, so providers on the platform continue to prescribe the treatment they determine is right for each patient. The financial terms of the agreement were not disclosed.
Why Lilly Chose a Telehealth Channel
Lilly said adults with obesity have shown strong and growing interest in getting care, including prescription medicines, through telehealth providers, especially as more FDA-approved GLP-1 treatments have become available. Ilya Yuffa, president of Lilly USA, said the company wants to meet patients where they already are, and that the agreement gives those patients a simple, more direct way to get FDA-approved Lilly medicine at an affordable price if prescribed.
Lilly is the second large GLP-1 maker to sell through Hims & Hers. Novo Nordisk has offered Wegovy and Ozempic on the platform since March, according to Fierce Healthcare. Hims & Hers, which says its weight-loss membership includes round-the-clock access to a care team, nutrition guidance and regular check-ins, now carries branded obesity medicines from both companies. Hims & Hers shares rose 8% on the day of the announcement, Fierce Healthcare reported.
Why This Matters for Healthcare Organizations
For clinics, the most immediate effect is on the patient in the room. A patient may now arrive already taking a branded GLP-1 prescribed through a telehealth platform and shipped to their home, and the clinician's job is to fit that treatment into the patient's wider care. Because these are self-pay purchases, they sit outside the patient's insurance benefit: the plan pays nothing and the fill does not appear as a plan claim, which is worth knowing when reconciling a medication list.
For practices that offer weight management themselves, the deal is a reminder that the channel is now part of the competition. A patient can move from an online consultation to home delivery without visiting a clinic at all. The compounded-medicines commitment also matters: after years of dispute over compounded GLP-1 copies, a large telehealth platform has now publicly committed to selling only the FDA-approved products, which sets a clearer standard for the rest of the market.
Analysis: Pharma Meets the Consumer Platform
The deal is less about two medicines than about distribution. Drugmakers have long sold through pharmacies and clinics; selling through a consumer telehealth platform puts the prescription, the payment and the delivery in one place, and puts the brand in front of a large audience that already uses the platform for care. The cash-pay model is part of the point: it avoids the prior authorisation and coverage limits that slow GLP-1 access through insurance, at the cost of leaving the patient to pay the full price.
What is not yet known is scale. The companies gave no sales or patient targets and no financial terms, so it is too early to say how many patients will use the channel. The questions to watch are whether other drugmakers follow with their own platform deals, and how insurers and in-person clinics respond as more prescribing moves online.
Clinics reviewing how patient communication and follow-up work can be handled can explore MedClinicX's AI patient portal, see how after-hours calls are handled on our AI medical receptionist page, or explore the demos and request a quote. For related coverage, see our earlier articles on CMS finalising a permanent framework for Medicare drug price negotiation and Part D premiums projected to rise in 2027.
Sources and References
- Eli Lilly and Company — Lilly and Hims & Hers expand access to FDA-approved Lilly medicines, 6 November 2026: https://investor.lilly.com/news-releases/news-release-details/lilly-and-hims-hers-expand-access-fda-approved-lilly-medicines
- Reuters — Lilly to sell obesity drugs directly on Hims & Hers site, 6 November 2026: https://www.reuters.com/legal/litigation/lilly-sell-obesity-drugs-directly-hims-hers-site-2026-11-06/
- Pharmaceutical Executive — Hims & Hers Partners with Eli Lilly to Sell Obesity Medicines, 6 November 2026: https://www.pharmexec.com/view/hims-hers-partners-eli-lilly-sell-obesity-medicines
Reporting based on the sources above, accessed 8 November 2026. The Lilly press release was read directly, and the Reuters and Pharmaceutical Executive reports were read directly and cross-checked against it. MedClinicX did not conduct original reporting or interviews for this article. Corrections: contact us via https://medclinicx.com/contact